EHA 2023 | Azacitidine, venetoclax & gilteritinib in older/unfit patients with FLT3-mutated AML
Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the rationale and findings from a Phase II study evaluating the combination of gilteritinib with azacitidine and venetoclax in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. The study reported encouraging efficacy results, with high rates of complete remission, high rates of measurable residual disease (MRD) negativity, and a two-year survival of around 70%. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Consultancy; Astellas: Research Funding; Takeda Oncology: Consultancy, Research Funding; Pfizer: Consultancy; Stemline Therapeutics: Research Funding; AstraZeneca: Consultancy; Amgen: Consultancy, Honoraria.
